AR078886A1 - Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades - Google Patents

Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades

Info

Publication number
AR078886A1
AR078886A1 ARP100104082A ARP100104082A AR078886A1 AR 078886 A1 AR078886 A1 AR 078886A1 AR P100104082 A ARP100104082 A AR P100104082A AR P100104082 A ARP100104082 A AR P100104082A AR 078886 A1 AR078886 A1 AR 078886A1
Authority
AR
Argentina
Prior art keywords
factor
amino acid
seq
acid residues
machine
Prior art date
Application number
ARP100104082A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR078886A1 publication Critical patent/AR078886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
ARP100104082A 2009-11-04 2010-11-04 Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades AR078886A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28046009P 2009-11-04 2009-11-04
US28171609P 2009-11-20 2009-11-20

Publications (1)

Publication Number Publication Date
AR078886A1 true AR078886A1 (es) 2011-12-07

Family

ID=43303899

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104082A AR078886A1 (es) 2009-11-04 2010-11-04 Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades

Country Status (14)

Country Link
US (1) US20110165648A1 (enExample)
EP (1) EP2496695A1 (enExample)
JP (1) JP2013509866A (enExample)
KR (1) KR20120120153A (enExample)
CN (1) CN102666850A (enExample)
AR (1) AR078886A1 (enExample)
BR (1) BR112012011607A2 (enExample)
CA (1) CA2782481A1 (enExample)
IN (1) IN2012DN03338A (enExample)
MX (1) MX2012005430A (enExample)
RU (1) RU2012122700A (enExample)
TW (1) TW201121993A (enExample)
WO (1) WO2011057014A1 (enExample)
ZA (1) ZA201202602B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
AU2016344133A1 (en) * 2015-10-30 2018-05-17 Genentech, Inc. Anti-Factor D antibody formulations
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5244800A (en) * 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
TW201716437A (zh) * 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Also Published As

Publication number Publication date
EP2496695A1 (en) 2012-09-12
BR112012011607A2 (pt) 2020-06-02
CA2782481A1 (en) 2011-05-12
IN2012DN03338A (enExample) 2015-10-23
US20110165648A1 (en) 2011-07-07
WO2011057014A1 (en) 2011-05-12
TW201121993A (en) 2011-07-01
MX2012005430A (es) 2012-06-19
JP2013509866A (ja) 2013-03-21
CN102666850A (zh) 2012-09-12
RU2012122700A (ru) 2013-12-10
ZA201202602B (en) 2013-06-26
KR20120120153A (ko) 2012-11-01

Similar Documents

Publication Publication Date Title
AR078886A1 (es) Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades
ES2602971T3 (es) Composición de anticuerpo modificado
Fry et al. Novel transcripts in the maxillary venom glands of advanced snakes
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
Mulenga et al. A mblyomma americanum tick saliva serine protease inhibitor 6 is a cross‐class inhibitor of serine proteases and papain‐like cysteine proteases that delays plasma clotting and inhibits platelet aggregation
CL2008003089A1 (es) Metodo para tratar enfermedad de alzheimer que comprende un regimen de un anticuerpo que se un epitopo en el n-terminal del peptido amiloide beta, anticuerpo humanizado contra la proteina amiloide beta que tiene sustituidas las posiciones 234, 235, y 237 por alanina en la region constante de las cadenas pesadas.
PE20212075A1 (es) PROTEINAS DE FUSION Fc IL-22 Y METODOS DE USO
CR9576A (es) METODOS PARA PURIFICAR PROTEINAS QUE CONTIENE LA REGION Fc
PE20090766A1 (es) Anticuerpo igg1 humanizado
PE20080036A1 (es) Anticuerpos humanos para la interleucina-13 (il13)
RU2012110578A (ru) Способы и композиции для лечения фиброзных заболеваний легких
HRP20150807T1 (hr) PRIPRAVCI KOJI SADRŽE PROTUTIJELO, ILI NJEGOV FRAGMENT, SPECIFIÄŚNO ZA aP2, NAMIJENJENO UPOTREBI U LIJEÄŚENJU DIJABETESA, NEPODNOŠENJA GLUKOZE ILI OTPORNOSTI NA INZULIN UZROKOVANE PRETILOŠÄ†U
JP2016536315A5 (enExample)
MX343630B (es) Medios y metodos para diagnosticar y tratar esclerosis multiple.
O'Shaughnessy et al. Natural history of proximal deep vein thrombosis assessed by duplex ultrasound.
Tan et al. Sharp-nosed Pit Viper (Deinagkistrodon acutus) from Taiwan and China: A comparative study on venom toxicity and neutralization by two specific antivenoms across the Strait
Parkinson et al. Development of an acid challenge-based in vitro dentin disc occlusion model.
Zhang et al. Enzyme activity of Schistosoma japonicum cercarial elastase SjCE-2b ascertained by in vitro refolded recombinant protein
Bafwafwa et al. Risk factors affecting mortality in children with pulmonary tuberculosis in lubumbashi, democratic republic of the Congo
Robbins et al. Macromolecules from living and fossil biominerals: Implications for the establishment of molecular phylogenies
Ferreira et al. Complete amino-acid sequence, crystallization and preliminary X-ray diffraction studies of leucurolysin-a, a nonhaemorrhagic metalloproteinase from Bothrops leucurus snake venom
Salazar et al. Design of a peptide-carrier vaccine based on the highly immunogenic Fasciola hepatica leucine aminopeptidase
MX2019014863A (es) Metodo para lavar articulo duro.
Magand et al. Autochthonous cutaneous sporotrichosis in France
Al-Omoush et al. The burden of psoriasis across United States: findings from the 2019 global burden of diseases study and forecasts from 2025 to 2035

Legal Events

Date Code Title Description
FB Suspension of granting procedure